AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00625664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 1 hour infusion administered on day 1, 30 minutes after the other treatment
Study NCT00625664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 1 hour infusion administered on day 1, 30 minutes after the other treatment
Study NCT02215980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02215980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02526030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Study NCT02526030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Study NCT02526030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Study NCT02937402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with Bronchoalveolar Lavage
Description: Undergo bronchoscopy with bronchoalveolar lavage
Study NCT02937402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Laboratory Biomarker Analysis
Study NCT00508664 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation start in week 11
Study NCT00508664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
Study NCT00508664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 i.v. day 1 3 times
Study NCT00508664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (TP)
Description: 75 mg/m2 i.v. day 1 3 times
Study NCT00508664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (TPF) (only until Feb 2009)
Description: Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
Study NCT04628455 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Inversion and snaring
Description: Vertical umbilical 5-mm incision was made for 5-mm trocar. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min keeping intraabdominal pressure between 8-12 mmHg. A two-mm incision was done at a point B \[midway between umbilicus and symphysis pubis\] for 2-mm port passed under direct vision and a tiny 11-blade scalpel puncture is done at the corresponding Mac-Burney's \[Point C\] for SGD.~Both SGDs were used to invert the hernia sac by gradual sustained alternating traction on the round ligament. Each SGD hands to the other one till complete inversion occurs, this is known by the hernial sac hanging from internal ring without retracting-back inside the inguinal canal. Then, the MPS is introduced via 2-mm trocar at point. SGD-C passed inside the loop of MPS and re-catches the hernial sac, which is then twisted around its neck several times. MPS was closed at the neck and diathermy current is applied. Detached sac was then pushed antigradely out through the umbilical port.
Study NCT02290743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.
Study NCT02750020 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
Study NCT00747357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon SeQuent Please
Description: Drug Eluting Balloon is followed by Bare Metal Stent
Study NCT00747357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon SeQuent Please
Description: Bare Metal Stent followed by Drug Eluting Balloon
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride Injection
Description: Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etomidate Fat Emulsion Injection
Description: 1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate Fat Emulsion Injection
Description: 1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: 2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
Study NCT01777152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Study NCT01777152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam Injection
Description: 0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Injection
Description: 0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
Study NCT04491656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WALANT Technique
Description: A technique commonly used in hand surgeries where the combination of lidocaine and epinephrine is used for local blood control, thus performing the procedure without a tourniquet
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl Citrate Injection
Description: 3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
Study NCT03264430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: an antagonist of the NMDA receptor
Study NCT03264430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: local anaesthetic
Study NCT03264430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: local anaesthetic
Study NCT01956812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU-107
Description: Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
Study NCT01956812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
Study NCT01956812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
Study NCT01956812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
Study NCT01991132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MediView 2.0 software
Study NCT02580500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Description: epidural anaesthesia application for spinal catheter will be used
Study NCT02580500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal catheter
Description: spinal anesthesia application for spinal catheter will be used
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate Injection
Description: 3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium Injection
Description: 0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
Study NCT02141737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Injection
Description: 0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
Study NCT01689493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient education and daily SMS
Description: The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
Study NCT02916537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1057
Description: Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
Study NCT02916537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Radical prostatectomy with lymph node dissection
Study NCT01136785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active CPAP Therapy
Description: 7 days of active CPAP therapy
Study NCT01136785 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham CPAP therapy
Description: 7 days of sham CPAP therapy
Study NCT03039946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop GDFT
Description: Patients receive fluids in the form of 100ml boluses of crystalloid (Plasmalyte) over 6 minutes via an automated closed-loop goal-directed fluid therapy (GDFT) system guided by non-invasive flow monitoring (Clearsight system). Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
Study NCT03039946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Fluid Therapy
Description: Patients receive fluids (Plasmalyte) via a restrictive approach with a baseline of of 4ml/kg/h. Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
Study NCT00666484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT06771635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concurrent
Description: The concurrent training program is divided into three types of training: endurance, cardiovascular and neuromotor.~Resistance training sessions were performed in a circuit format with >30 rest periods between exercises. The volume of work ranged from 8 to 12 repetitions at 60% of the estimated 1 maximum repetition (RM).~The cardiovascular work time per session ranged from 25-50 min depending on the intensity of the exercise and the intensity was regulated according to the maximum heart rate (FHR) estimated for each subject between 60-75%~The neuromotor training intensity of the sessions was low. The participants wore a heart rate monitor and were instructed not to exceed 60% of their HRF
Study NCT06771635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Non training intervention
Study NCT00666484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00666484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00666484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Study NCT00666484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Study NCT00666484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00666484 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03035877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy-Emerging Adults
Description: MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
Study NCT03035877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
Study NCT04164511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)
Description: The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.
Study NCT00738478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasogastric tube
Description: insertion of nasogastric tube for 2 days after operation
Study NCT00738478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: without nasogastric tube
Description: without nasogastric tube after operation
Study NCT03581851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude: (FiO2: 15.1)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.
Study NCT04321447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical practice guideline for prevention and management of extravasation injury
Description: Implementation of an evidence-based clinical practice guideline and delivery of an educational programme for nurses
Study NCT02070198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting FSH and GnRH antagonist
Description: Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
Study NCT02070198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily FSH and GnRH antagonist
Description: Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
Study NCT02070198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin and recombinant FSH
Description: Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
Study NCT03581851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.
Study NCT02652884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phosphate and betamethasone acetate, 2 mL.
Description: single dose of intramuscular depot corticosteroid
Study NCT02652884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9% NaCl
Description: single dose of intramuscular placebo
Study NCT02005757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bredinin tablet 150mg
Description: Bredinin 150mg qd vs Bredinin 50mg tid
Study NCT02005757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bredinin tablet 50mg
Description: Bredinin 150mg qd vs Bredinin 50mg tid
Study NCT01707407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg pomalidomide capsule administered orally once in the morning
Study NCT01232803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Description: Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
Study NCT01232803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% N-9 gel
Description: Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
Study NCT01232803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo gel
Description: Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
Study NCT01683097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized explanation
Description: Standardized explanation provided on code status, advance directives and end of life care
Study NCT02756806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond Q-switched laser
Description: Each subject will receive laser treatments with Enlighten laser
Study NCT04565743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support on dentification and treatment of patients with high risk of osteoporotic fractures
Description: Education for primary care health care professionals and referral of patients with recent osteoporotic fracture.
Study NCT01806701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy
Description: the 'gold-standard' behavioral treatment for children/adolescents with posttraumatic stress disorder
Study NCT05605938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoten for children
Description: Oral administration
Study NCT05605938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT03307655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (fertile semen donors)
Description: The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined.
Study NCT03307655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients (subfertile men)
Description: The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined.
Study NCT00660686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
Study NCT00660686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Training
Description: 60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
Study NCT03449524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 75mg CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
Study NCT03449524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150mg CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
Study NCT03449524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02587377 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non Standard of Care blood samples collection
Description: According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
Study NCT00932828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Description: Defatted peanut in flour form to be used as treatment for peanut allergy